Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cystic Diseases of the Kidney Clinical Presentation

  • Author: Thomas Patrick Frye, DO; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
 
Updated: Jan 28, 2015
 

History

Presentation in patients with renal cysts varies with the underlying disease.

Developmental cystic renal disease

Multicystic dysplastic kidney (MCDK) is almost uniformly identified during prenatal sonographic examination. The involved kidney partially or completely improves with age in 40-90% of patients.[17] Bilateral renal involvement is not compatible with life.

MCDK can exist independently or as part of syndromes such as the vertebral defects, anal atresia, tracheoesophageal fistula with esophageal atresia, and radial and renal anomalies (VATER) association; Zellweger syndrome; or BOR syndrome.[18]

Inherited cystic renal disease

Inherited cystic renal disease includes the following disorders:

  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Autosomal recessive polycystic kidney disease (ARPKD)
  • Glomerulocystic kidney disease (GCKD)
  • Juvenile nephronophthisis (JNPHP)
  • Medullary cystic kidney disease

Autosomal dominant polycystic kidney disease

Manifestations of ADPKD vary by patient age, as follows:

  • Patients present in the fourth decade of life with flank pain or intermittent hematuria
  • Patients may also experience cyst hemorrhage, renal infection, or nephrolithiasis
  • Hypertension and chronic renal failure are noted in the fifth decade of life
  • Patients progress to end-stage renal disease (ESRD) in the sixth decade of life
  • Hypertension is seen in 50% of patients with ADPKD aged 20-34 years

The disease course varies considerably among affected individuals. While all gene carriers are believed to exhibit symptoms by the end of their eighth decade of life, only 50% of carriers actually progress to renal failure. Kidney size (a direct reflection of cyst volume) increases exponentially over time and appears symmetric in a given individual, with an equal growth rate in both kidneys.[19]

All aspects of the disease appear to develop more significantly in patients with the PKD1 genotype. Despite similar rates of cystic growth, these patients develop more cysts at a younger age than patients with PKD2 mutations, and subsequently develop hypertension and ESRD at a younger age; the onset of ESRD in persons with the PKD1 genotype occurs at a mean age of 53 years, while the onset of ESRD in persons with the PKD2 genotype occurs at a mean age of 69 years.[5]

In addition, studies have suggested that the type of PDK1 mutation also affects prognosis. In one series, patients with non-truncating mutations (about 20%) developed ESRD 12 years later than those with truncating mutations, at 67.9 versus 55.6 years of age, respectively.[20]

Hepatic cysts are the most common extrarenal manifestation of ADPKD. These increase in number with age (20% in the third decade of life, 75% after the sixth decade of life) and may cause chronic pain. However, even with extensive cystic involvement, liver function is not compromised.

In a study of 558 patients with ADPKD, hepatomegaly was common even in early-stage disease and was not accounted for by cysts alone. Compared with the liver volumes of patients without ADPKD, parenchymal volumes were larger, even in patients who did not have cysts. Polycystic liver disease severity was associated with altered biochemical and hematologic laboratory tests and a lower quality of life.[21]

Other clinical associations in ADPKD include the following:

  • Cardiac valve disease (particularly mitral valve prolapse [25%])
  • Diverticulosis
  • Cerebral aneurysms (5-10%)
  • Pancreatic cysts
  • Seminal vesicle cysts [4]

Autosomal recessive polycystic kidney disease

ARPKD affects renal and hepatic development (dysgenesis of the portal triad). However, the degree of organ involvement varies in relation to the age of onset.

In the neonatal period, pulmonary disease, resulting from nephromegaly and oligohydramnios, dominates the presentation. Typically, the neonate has profound respiratory compromise, often exacerbated by pneumothorax or pulmonary hypoplasia. This presentation may result in neonatal death.

Symptoms in infancy include hypertension (80%), diminished urine-concentrating ability, renal insufficiency, and subsequent electrolyte abnormalities. Most affected children develop hypertension within the first few years of life. Growth retardation has been reported in one fourth of children. Up to 26.5% develop significant hyponatremia.[22] Fifty percent of affected individuals develop ESRD in the first decade of life, requiring dialysis or transplantation.

In older children (4-8 y), the kidneys often are less severely affected, while hepatic disease may predominate. Hepatic involvement usually presents with symptoms secondary to portal hypertension, particularly varices and splenomegaly. Twenty-three percent of children with ARPKD experience variceal bleeding by a mean age of 12.5 years. Hepatic disease may also result in acute bacterial cholangitis or thrombocytopenia secondary to hypersplenism.

Glomerulocystic kidney disease

GCKD occurs in early (neonatal) and late (adult) forms. Neonates present with hypertension, abdominal masses, and variable degrees of renal failure. Adults typically present with flank pain, hematuria, and hypertension. Hepatic cysts may also develop.[7]

Juvenile nephronophthisis

JNPHP has several different phenotypic expressions, depending on the gene involved. Infantile (NPHP2), juvenile (NPHP1, NPHP4) and adolescent (NPHP3) forms of the disease exist, but most symptoms appear during the first decade of life. These include growth retardation, urine concentrating defects (polyuria and polydipsia), skeletal dysplasia, anemia, and progressive renal failure. Additionally, some degree of hepatic fibrosis and biliary duct enlargement is usually present.[2] Cysts usually occur secondary to ESRD and in the corticomedullary junction.

Medullary cystic kidney disease

This disorder is clinically milder than JNPHP, occurs later in life (third to fourth decades), and has limited extrarenal manifestations. Individuals with this disease due to mutations in the MCKD2 gene present with uremia sooner than those with disease due to MCKD1 mutations and are more likely to develop hyperuricemia and gout.[2]

Systemic disease with associated renal cysts

Clinical features of tuberous sclerosis (TS) include facial nevi, cardiac rhabdomyomas, epilepsy, angiofibromas, and mental retardation. Approximately one half of patients have multiple renal angiomyolipomas. Twenty to 25% of patients have renal cysts, although diffuse renal cystic disease, which may result in chronic renal failure, is rare.

Clinical features of von Hippel-Lindau syndrome (VHLS) include retinal and cerebellar hemangioblastomas, pheochromocytomas, and cystic disease of the kidneys, pancreas, and epididymis. Renal cysts are very common, occurring in two thirds of patients. Renal cell carcinoma (RCC) develops in as many as 40% of patients.

Acquired cystic renal disease

Acquired renal cystic disease (ARCD) may be found in patients with all etiologies of ESRD, particularly in those who are dialysis dependent. The incidence, number, and size of cysts all increase in proportion to the duration of dialysis. Most patients are asymptomatic, but symptoms may include gross hematuria, flank pain, renal colic, or a palpable renal mass. Hemorrhagic cysts occur in 50% of patients.[14]

Medullary sponge kidney (MSK) is usually detected on radiographic evaluation of adults with nephrolithiasis. Fifteen to 20% of patients with calcium oxalate and calcium phosphate renal calculi have MSK. Patients may also have a history of hematuria or urinary tract infection (UTI). Most patients with MSK, however, are asymptomatic. Approximately 10% of patients develop recurrent nephrolithiasis, bacteriuria, and pyelonephritis. Involvement is usually bilateral.

Simple cysts usually are clinically silent. Occasionally, however, they hemorrhage and cause acute pain.

Next

Physical Examination

In developmental cystic renal disease, MCDK may be palpable as a flank mass in an otherwise healthy infant. MCDK is the most common cause of a renal mass and the second most common cause of a palpable abdominal mass in neonates.[23, 3]

Inherited cystic renal disease produces the following findings:

  • ARPKD: Bilateral flank masses are palpable in 30% of neonates and infants with this disease; older children may demonstrate signs of portal hypertension
  • ADPKD: The enlarged kidneys and liver may be palpable

In acquired cystic renal disease, simple cysts rarely become large enough to be palpable.

Previous
 
 
Contributor Information and Disclosures
Author

Thomas Patrick Frye, DO Clinical Fellow, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health

Disclosure: Nothing to disclose.

Coauthor(s)

Steven Abboud Research Fellow, Medical Research Scholars Program, National Cancer Institute, National Institutes of Health

Steven Abboud is a member of the following medical societies: American Medical Association, American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Additional Contributors

Edmund S Sabanegh, Jr, MD Chairman, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation

Edmund S Sabanegh, Jr, MD is a member of the following medical societies: American Medical Association, American Society of Andrology, Society of Reproductive Surgeons, Society for the Study of Male Reproduction, American Society for Reproductive Medicine, American Urological Association, SWOG

Disclosure: Nothing to disclose.

Acknowledgements

John M Corman, MD Clinical Associate Professor of Urology, University of Washington at Seattle; Consulting Staff, Department of Urology, Virginia Mason Medical Center

Disclosure: Nothing to disclose.

Alex Gorbonos, MD Assistant Professor, Department of Urology, Loyola University School of Medicine

Alex Gorbonos, MD is a member of the following medical societies: Alpha Omega Alpha, American Urological Association, Endourological Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Justin A Siegal, MD Radiologist, Department of Radiology, Virginia Mason Medical Center

Disclosure: Nothing to disclose.

Andrew T Trout, MD Resident Physician, Department of Radiology, University of Michigan Medical School

Andrew T Trout is a member of the following medical societies: American Medical Association, Phi Beta Kappa, Radiological Society of North America, and Sigma Xi

Disclosure: Nothing to disclose.

References
  1. Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke. 2011 Jan. 42(1):204-6. [Medline].

  2. Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A. Renal cystic diseases: a review. Adv Anat Pathol. 2006 Jan. 13(1):26-56. [Medline].

  3. Kalyoussef E, Hwang J, Prasad V, Barone J. Segmental multicystic dysplastic kidney in children. Urology. 2006 Nov. 68(5):1121.e9-11. [Medline].

  4. Avner ED, Sweeney WE. Renal cystic disease: new insights for the clinician. Pediatr Clin North Am. 2006 Oct. 53(5):889-909, ix. [Medline].

  5. Wilson PD. Polycystic kidney disease. N Engl J Med. 2004 Jan 8. 350(2):151-64. [Medline].

  6. Gunay-Aygun M, Avner ED, Bacallao RL, Choyke PL, Flynn JT, Germino GG, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr. 2006 Aug. 149(2):159-64. [Medline].

  7. Gusmano R, Caridi G, Marini M, Perfumo F, Ghiggeri GM, Piaggio G, et al. Glomerulocystic kidney disease in a family. Nephrol Dial Transplant. 2002 May. 17(5):813-8. [Medline].

  8. Guay-Woodford LM. Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex. Pediatr Nephrol. 2006 Oct. 21(10):1369-76. [Medline].

  9. Saunier S, Salomon R, Antignac C. Nephronophthisis. Curr Opin Genet Dev. 2005 Jun. 15(3):324-31. [Medline].

  10. Mostov KE. mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006 Apr 4. 103(14):5247-8. [Medline].

  11. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. PNAS. 2006 Apr 4. 103:5466-5471. [Medline].

  12. Baradhi KM, Abuelo GJ. Unilateral renal cystic disease. Kidney Int. 2012 Jan. 81(2):220. [Medline].

  13. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009. 60:321-37. [Medline]. [Full Text].

  14. Thomsen HS, Levine E, Meilstrup JW, Van Slyke MA, Edgar KA, Barth JC, et al. Renal cystic diseases. Eur Radiol. 1997. 7(8):1267-75. [Medline].

  15. Choyke PL. Acquired cystic kidney disease. Eur Radiol. 2000. 10(11):1716-21. [Medline].

  16. Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, et al. Polycystic kidney disease and cancer after renal transplantation. J Am Soc Nephrol. 2014 Oct. 25(10):2335-41. [Medline]. [Full Text].

  17. Siqueira Rabelo EA, Oliveira EA, Silva JM, Oliveira DS, Colosimo EA. Ultrasound progression of prenatally detected multicystic dysplastic kidney. Urology. 2006 Nov. 68(5):1098-102. [Medline].

  18. Welch TR, Wacksman J. The changing approach to multicystic dysplastic kidney in children. J Pediatr. 2005 Jun. 146(6):723-5. [Medline].

  19. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18. 354(20):2122-30. [Medline].

  20. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013 May. 24(6):1006-13. [Medline]. [Full Text].

  21. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clin Gastroenterol Hepatol. 2014 Aug 9. [Medline].

  22. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003 May. 111(5 Pt 1):1072-80. [Medline].

  23. Onal B, Kogan BA. Natural history of patients with multicystic dysplastic kidney-what followup is needed?. J Urol. 2006 Oct. 176(4 Pt 1):1607-11. [Medline].

  24. Torres, Vicente, Harris, Peter, Yves, Pirson. Autosomal dominant polycystic kidney disease. The Lancet. April 14, 2007. 369:1287-1301.

  25. Bergmann C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol. 2015 Jan. 30(1):15-30. [Medline]. [Full Text].

  26. Mercado-Deane MG, Beeson JE, John SD. US of renal insufficiency in neonates. Radiographics. 2002 Nov-Dec. 22(6):1429-38. [Medline].

  27. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan. 1(1):64-9. [Medline].

  28. [Guideline] Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr. 2014 Sep. 165(3):611-7. [Medline].

  29. Chaumoitre K, Brun M, Cassart M, Maugey-Laulom B, Eurin D, Didier F, et al. Differential diagnosis of fetal hyperechogenic cystic kidneys unrelated to renal tract anomalies: A multicenter study. Ultrasound Obstet Gynecol. 2006 Dec. 28(7):911-7. [Medline].

  30. Hawkins JS, Dashe JS, Twickler DM. Magnetic resonance imaging diagnosis of severe fetal renal anomalies. Am J Obstet Gynecol. 2008 Mar. 198(3):328.e1-5. [Medline].

  31. Zaretsky M, Ramus R, McIntire D, Magee K, Twickler DM. MRI calculation of lung volumes to predict outcome in fetuses with genitourinary abnormalities. AJR Am J Roentgenol. 2005 Nov. 185(5):1328-34. [Medline].

  32. Borges Oliva MR, Hsing J, Rybicki FJ, Fennessy F, Mortele KJ, Ros PR. Glomerulocystic kidney disease: MRI findings. Abdominal Imaging. 2003 Nov. 28:889-892. [Medline].

  33. Song C., et al. Differential Diagnosis of Complex Cystic Renal Mass Using Multiphase Computerized Tomography. Journal of Urology. 2009/06. 181:2446-2450.

  34. Ellimoottil C, Greco KA, Hart S, Patel T, Sheikh MM, Turk TM, et al. New Modalities for Evaluation and Surveillance of Complex Renal Cysts. J Urol. 2014 Dec. 192(6):1604-1611. [Medline].

  35. Linguraru MG, Yao J, Gautam R, Peterson J, Li Z, Linehan WM, et al. Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT. Pattern Recognit. 2009 Jun 1. 42(6):1149-1161. [Medline]. [Full Text].

  36. Kim WB, Lee SW, Doo SW, Yang WJ, Song YS, Jeon JS, et al. Category migration of renal cystic masses with use of gadolinium-enhanced magnetic resonance imaging. Korean J Urol. 2012 Aug. 53(8):573-6. [Medline]. [Full Text].

  37. Bosniak MA. The use of the Bosniak classification system for renal cysts and cystic tumors. J Urol. 1997 May. 157(5):1852-3. [Medline].

  38. Garcia-Rojo, D. Comparison of Contrast-Enhanced Ultrasound (CE-US) and Computed Tomography (CT) in the Evaluation of Complex Cystic Renal Masses. Journal of Urology. May 31, 2010. 183:e243.

  39. Smith AD, Remer EM, Cox KL, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology. 2012 Jan. 262(1):152-60. [Medline].

  40. Li, G.,, et al. CA9 molecular marker for differential diagnosis of cystic renal tumors. Urologic Oncology. Sept. 3, 2010.

  41. Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006 Jan. 2(1):40-55; quiz 55. [Medline].

  42. Zerem, E. Simple renal cysts and arterial hypertension: does their evacuation decrease the blood pressure?. Journal of Hypertension. Oct. 27, 2009. 10:2074-2078.

  43. [Guideline] Levels of neonatal care. Pediatrics. 2012 Sep. 130(3):587-97. [Medline].

  44. Guay-Woodford L. Other Cystic Diseases. Johnson R, Feehally J. Comprehensive Clinical Nephrology. 4th. London: Mosby; 2010. 543-559.

  45. Rheault MN, Rajpal J, Chavers B, Nevins TE. Outcomes of infants 11111111111Pediatr Nephrol</i>. 2009 Oct. 24(10):2035-9. [Medline].

  46. Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009 Oct 22. 361(17):1639-50. [Medline].

  47. Serra A., et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine. Aug. 26, 2010. 9:820-829.

  48. Wüthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother. 2014 Jun. 15(8):1085-95. [Medline].

  49. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20. 367(25):2407-18. [Medline]. [Full Text].

  50. Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract. 2012. 120(1):c25-34; discussion c35. [Medline].

  51. Aguiari G, Catizone L, Del Senno L. Multidrug therapy for polycystic kidney disease: a review and perspective. Am J Nephrol. 2013. 37(2):175-82. [Medline].

  52. Rane, A. Laparoscopic management of symptomatic simple renal cysts. International Urology Nephrology. 2004. 36:5-9.

  53. Emre, H. "Stepped procedure" in laparoscopic cyst decortications during the learning period of laparoscopic surgery: Detailed evaluation of initial experiences. Journal of Minimal Access Surgery. Apr 6, 2010. 2:37-41.

  54. Kilciler, M. Finger assisted laparoscopic renal cyst excision: a simple technique. Urology Journal. Jun 10, 2010. 7:90-94.

  55. Busato, W. Percutaneous endocystolysis, a safe and minimally invasive treatment for renal cysts: a 13-year experience. Journal of Endourology. Sept. 2010. 24:1405-1410.

  56. Lucas, S. Staged Nephrectomy Versus Bilateral Laparoscopic Nephrectomy in Patients with Autosomal Dominant Polycycstic Kidney Disease. Journal of Urology. Nov. 2010. 184:2054-2059.

  57. Agarwal M, Agrawal MS, Mittal R, Sachan V. A randomized study of aspiration and sclerotherapy versus laparoscopic deroofing in management of symptomatic simple renal cysts. J Endourol. 2012 May. 26(5):561-5. [Medline].

  58. Webster, W. Surgical Resection Provides Excellent Outcomes for Patients with Cystic Clear Cell Renal Cell Carcinoma. Urology. May 2007. 900-904.

  59. Bloom DA, Brosman S. The multicystic kidney. J Urol. 1978 Aug. 120(2):211-5. [Medline].

  60. Bonsib SM. Non-neoplastic diseases of the kidney. Bostwick DG. Urologic Surgical Pathology. St Louis, Mo: Mosby-Year Book; 1997.

  61. Bosniak MA. How does one deal with a renal cyst that appears to be Bosniak class II on a CT scan but that has sonographic features suggestive of malignancy (e.g., nodularity of wall or a nodular, irregular septum)?. AJR Am J Roentgenol. 1994 Jul. 163(1):216. [Medline].

  62. Bosniak MA. The current radiological approach to renal cysts. Radiology. 1986 Jan. 158(1):1-10. [Medline].

  63. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. 1994 Dec. 8(4):328-32. [Medline].

  64. Chapman T. Fetal genitourinary imaging. Pediatr Radiol. 2012 Jan. 42 Suppl 1:S115-23. [Medline].

  65. Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, et al. Renal involvement in von Hippel-Lindau disease. Kidney Int. 1996 Sep. 50(3):944-51. [Medline].

  66. Clarke A, Hancock E, Kingswood C, Osborne JP. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant. 1999 Apr. 14(4):988-91. [Medline].

  67. Davidson AJ, Hartman DS, Choyke PL, Wagner BJ. Radiologic assessment of renal masses: implications for patient care. Radiology. 1997 Feb. 202(2):297-305. [Medline].

  68. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995 Jun. 5(12):2048-56. [Medline].

  69. Freire M, Remer EM. Clinical and radiologic features of cystic renal masses. AJR Am J Roentgenol. 2009 May. 192(5):1367-72. [Medline].

  70. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008 Oct 2. 359(14):1477-85. [Medline].

  71. Grantham JJ, Nair V, Winklhofer F. Cystic disease of the kidney. Brenner BM, ed. Brenner and Rector's the Kidney. 6th ed. Philadelphia, Pa: WB Saunders Co; 2000. 1171-1200.

  72. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006 Nov. 17(11):3013-9. [Medline].

  73. Israel GM, Bosniak MA. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am J Roentgenol. 2003 Sep. 181(3):627-33. [Medline].

  74. Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004 May. 231(2):365-71. [Medline].

  75. Lang EK, Macchia RJ, Gayle B, Richter F, Watson RA, Thomas R. CT-guided biopsy of indeterminate renal cystic masses (Bosniak 3 and 2F): accuracy and impact on clinical management. Eur Radiol. 2002 Oct. 12(10):2518-24. [Medline].

  76. Laube M, Hess B, Terrier F, Vock P, Jaeger P. [Prevalence of medullary sponge kidney in patients with and without nephrolithiasis]. Schweiz Rundsch Med Prax. 1995 Oct 24. 84(43):1224-30. [Medline].

  77. Levine E, Slusher SL, Grantham JJ, Wetzel LH. Natural history of acquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. AJR Am J Roentgenol. 1991 Mar. 156(3):501-6. [Medline].

  78. Lonergan GJ, Rice RR, Suarez ES. Autosomal recessive polycystic kidney disease: radiologic-pathologic correlation. Radiographics. 2000 May-Jun. 20(3):837-55. [Medline].

  79. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore). 1990 Jul. 69(4):217-26. [Medline].

  80. Miller MA, Brown JJ. Renal cysts and cystic neoplasms. Magn Reson Imaging Clin N Am. 1997 Feb. 5(1):49-66. [Medline].

  81. Ohlson L. Normal collecting ducts: visualization at urography. Radiology. 1989 Jan. 170(1 Pt 1):33-7. [Medline].

  82. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994 Apr 2. 343(8901):824-7. [Medline].

  83. Siegel CL, McFarland EG, Brink JA, Fisher AJ, Humphrey P, Heiken JP. CT of cystic renal masses: analysis of diagnostic performance and interobserver variation. AJR Am J Roentgenol. 1997 Sep. 169(3):813-8. [Medline].

  84. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology. 2008 Oct. 249(1):16-31. [Medline].

  85. Tsatsaris V, Gagnadoux MF, Aubry MC, Gubler MC, Dumez Y, Dommergues M. Prenatal diagnosis of bilateral isolated fetal hyperechogenic kidneys. Is it possible to predict long term outcome?. BJOG. 2002 Dec. 109(12):1388-93. [Medline].

  86. Wolf JS Jr. Evaluation and management of solid and cystic renal masses. J Urol. 1998 Apr. 159(4):1120-33. [Medline].

  87. Yent ER. Medullary sponge kidney. Schrier RE, Gottschalk CW. Disease of the Kidney. 5th ed. Little Brown: Boston, Mass; 1993. 525-32.

 
Previous
Next
 
Cut surface of a nephrectomy specimen from a patient with a multicystic dysplastic kidney (MCDK).
Nephrectomy specimen from a patient with a large benign simple cyst.
External surface of a nephrectomy specimen from a patient with autosomal dominant polycystic kidney disease (ADPKD).
Cut surface of the same nephrectomy specimen from a patient with autosomal dominant polycystic kidney disease (ADPKD).
Cut section of nephrectomy specimen demonstrating renal cell carcinoma (RCC), with an adjacent simple cyst.
Close-up photograph of the cut surface of the same nephrectomy specimen demonstrating a simple cyst adjacent to a renal cell carcinoma (RCC).
A prenatal sonogram of a fetus with a multicystic dysplastic kidney. The right kidney is appreciated as a large multicystic paraspinal mass. The left kidney and bladder are normal, and a normal amount of amniotic fluid is present.
CT examination of the abdomen of a 70-year-old woman with autosomal dominant polycystic kidney disease (ADPKD) is shown. The kidneys are bilaterally enlarged with multiple cysts.
CT scan of the same patient (70-year-old woman with autosomal dominant polycystic kidney disease [ADPKD]) demonstrating multiple hepatic cysts.
This CT scan demonstrates acquired renal cystic disease (ARCD) in a 70-year-old man who is dialysis-dependent. The CT scan demonstrates bilateral atrophic kidneys with multiple renal cysts.
A CT scan of a 38-year-old man with von Hippel-Lindau syndrome (VHLS). The patient previously underwent resection of multiple bilateral renal cell carcinomas (RCCs). CT scan demonstrates multiple cysts in the kidneys and pancreas, as well as solid renal lesions suggestive of malignancy.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.